Published in J Clin Pathol on April 01, 2008
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest (2009) 2.55
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat (2013) 1.26
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol (2013) 1.19
Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer (2011) 1.19
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology (2011) 1.10
Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods (2014) 1.10
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer (2013) 1.09
Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology (2010) 1.03
Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am J Pathol (2011) 0.95
Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol (2014) 0.89
EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch (2012) 0.88
HER2 expression in gastric and oesophageal cancer: a meta-analytic review. J Gastrointest Oncol (2015) 0.87
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer (2010) 0.87
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One (2013) 0.83
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. J Cancer Res Clin Oncol (2013) 0.81
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. Br J Cancer (2014) 0.78
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol (2016) 0.78
Guidelines for cytogenetic investigations in tumours. Eur J Hum Genet (2015) 0.78
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast (2012) 0.77
Development of a single-cell array for large-scale DNA fluorescence in situ hybridization. Lab Chip (2013) 0.77
Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surg (2012) 0.76
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer. BMC Cancer (2016) 0.75
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. Br J Cancer (2017) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum. Nature (1990) 5.41
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Validity of accelerometry for the assessment of moderate intensity physical activity in the field. Med Sci Sports Exerc (2000) 4.60
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body. Cell (1990) 3.65
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
Role of the human transferrin receptor cytoplasmic domain in endocytosis: localization of a specific signal sequence for internalization. J Cell Biol (1990) 3.24
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast (2008) 2.96
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med (2000) 2.80
T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol (1997) 2.76
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Hemolysis by asbestos. Environ Res (1971) 2.41
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol (2004) 2.36
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 2.35
Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A (1997) 2.34
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol (2000) 2.34
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
Retroviral diversity and distribution in vertebrates. J Virol (1998) 2.22
Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr (1998) 2.21
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology (2006) 2.14
Total-body potassium in hypertension patients during prolonged diuretic therapy. Lancet (1972) 2.09
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology (1995) 2.02
Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods (2001) 2.01
Towards MRI guided surgical manipulator. Med Sci Monit (2001) 1.97
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy (1981) 1.96
Clinical features and outcome of severe malaria in Gambian children. Clin Infect Dis (1995) 1.96
A simple post-embedding system for the rapid demonstration of tissue antigens under the electron microscope. Histochem J (1983) 1.95
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94
Laparoscopic nephrectomy: the experience of the laparoscopy working group of the German Urologic Association. J Urol (1998) 1.93
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Changes in regional fat redistribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am J Clin Nutr (2001) 1.91
Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology (1995) 1.90
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res (2001) 1.90
Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol (1994) 1.88
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Evaluation of alternate coupling reagents to replace alpha-naphthyl amine for the detection of nitrate reduction. Microbios (1976) 1.85
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med (1999) 1.83
Reading the prognosis of the individual with breast cancer. Eur J Cancer (2007) 1.83
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol (2000) 1.81
Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ (1993) 1.79
Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol (1993) 1.78
Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology (1994) 1.78
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 1.78
Monoclonal antibodies against defined epitopes of the human transferrin receptor cytoplasmic tail. Biochim Biophys Acta (1992) 1.76
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene (2006) 1.74
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol (2011) 1.73
An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics (2002) 1.73
X-ray refraction effects: application to the imaging of biological tissues. Br J Radiol (2003) 1.73
Objective monitoring of physical activity using motion sensors and heart rate. Res Q Exerc Sport (2000) 1.73
Investigating fatigue of less than 6 months' duration. Guidelines for family physicians. Can Fam Physician (1999) 1.73